CYP19A1 Genetic Polymorphisms rs4646 and Osteoporosis in Patients Treated with Aromatase Inhibitor-Based Adjuvant Therapy

Mazzuca, Federica; Botticelli, Andrea; Mazzotti, Eva; La Torre, Marco; Borro, Marina; Marchetti, Luca; Maddalena, Chiara; Gentile, Giovanna; Simmaco, Maurizio; Marchetti, Paolo

doi:10.5152/eurasianjmed.2015.008

CYP19A1 Genetic Polymorphisms rs4646 and Osteoporosis in Patients Treated with Aromatase Inhibitor-Based Adjuvant Therapy

Copy For Citation

Mazzuca F., Botticelli A., Mazzotti E., La Torre M., Borro M., Marchetti L., ...More

EURASIAN JOURNAL OF MEDICINE, vol.48, no.1, pp.10-14, 2016 (Journal Indexed in ESCI)

Publication Type: Article / Article
Volume: 48 Issue: 1
Publication Date: 2016
Doi Number: 10.5152/eurasianjmed.2015.008
Title of Journal : EURASIAN JOURNAL OF MEDICINE
Page Numbers: pp.10-14

Abstract

Objective: Third-generation aromatase inhibitors (AI) are potent suppressors of aromatase activity. The aim of this study was to measure the incidence of adverse effects in breast cancer patients treated with AI-based adjuvant therapy and the relationship with the CYP19A1 genotypes.